Business Context and Reporting Period
Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) filed a Form 8-K on August 20, 2024, to announce a corporate action approved by its Board of Directors. The filing details the implementation of a previously authorized reduction in authorized shares and a reverse stock split.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Reverse Stock Split: The Board approved a 1-for-50 reverse stock split of the Company's Common Stock.
- Authorized Share Reduction: The total number of authorized shares of Common Stock will be reduced from 500,000,000 to 250,000,000.
- Effective Date: The actions will become effective at 5:00 P.M. (EST) on August 30, 2024.
- Trading Resumption: Shares are expected to begin trading on a split-adjusted basis under the symbol "MTNB" on September 3, 2024.
- Fractional Shares: No fractional shares will be issued; holders entitled to a fractional share will receive one whole share instead.
Outlook, Risks, and Management Commentary
Management anticipates that the reverse stock split will be sufficient to maintain compliance with NYSE American's continued listing standards. However, the filing explicitly states there can be no assurance that the split will enable the Company to maintain its listing. Following the split, the Company may consider targeting The Nasdaq Global Market or another tier for an "uplisting," which requires an initial bid price of at least $4.00 per share. The Company provides no assurance that it will pursue such a listing or that it will meet the minimum bid price requirements.
Investor Verification Checklist
- Verify the new CUSIP number (576810 303) for post-split trading.
- Confirm the exact number of shares held after the 1-for-50 conversion and the rounding up of fractional shares.
- Monitor the stock price on September 3, 2024, to assess compliance with NYSE American listing standards.
- Check for future announcements regarding potential uplisting to The Nasdaq Global Market.